These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 9538146)

  • 1. Neoadjuvant chemotherapy with accelerated CNF plus G-CSF in patients with breast cancer tumors larger than three centimeters: a pilot study.
    Lorusso V; Catino A; Schittulli F; Longo S; Racanelli A; Timurian A; Marzullo F; Simone G; Brandi M; De Lena M
    Int J Oncol; 1998 May; 12(5):1177-81. PubMed ID: 9538146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant cytotoxic and endocrine therapy in pre- and postmenopausal patients with breast cancer and one to nine infiltrated nodes: five-year results of the Hellenic Cooperative Oncology Group randomized HE 10/92 study.
    Fountzilas G; Stathopoulos G; Kouvatseas G; Polychronis A; Klouvas G; Samantas E; Zamboglou N; Kyriakou K; Adamou A; Pectasidis D; Ekonomopoulos T; Kalofonos HP; Bafaloukos D; Georgoulias V; Razis E; Koukouras D; Zombolas V; Kosmidis P; Skarlos D; Pavlidis N;
    Am J Clin Oncol; 2004 Feb; 27(1):57-67. PubMed ID: 14758135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients.
    van der Wall E; Rutgers EJ; Holtkamp MJ; Baars JW; Schornagel JH; Peterse JL; Beijnen JH; Rodenhuis S
    Br J Cancer; 1996 May; 73(9):1080-5. PubMed ID: 8624267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.
    Bennett JM; Muss HB; Doroshow JH; Wolff S; Krementz ET; Cartwright K; Dukart G; Reisman A; Schoch I
    J Clin Oncol; 1988 Oct; 6(10):1611-20. PubMed ID: 3049953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary chemotherapy in operable breast cancer with favorable prognostic factors: a pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN).
    Nolè F; Minchella I; Colleoni M; Orvieto E; Munzone E; de Braud F; Peruzzotti G; Martinelli G; Zampino MG; Catania C; Pizzamiglio M; Veronesi P; Zurrida S; Galimberti V; Goldhirsch A; Veronesi U
    Ann Oncol; 1999 Aug; 10(8):993-6. PubMed ID: 10509165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
    Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
    Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Feasibility of a cyclophosphamide methotrexate and 5-fluorouracil regime intravenously administered with and without granulocyte-colony stimulating factor in surgically treated breast carcinoma].
    Garrone O; Del Mastro L; Mariani GL; Ardizzoni A; Venturini M; Rosso R
    Minerva Med; 1993 Sep; 84(9):467-72. PubMed ID: 7504219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
    Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
    Rivkin SE; Green S; O'Sullivan J; Cruz AB; Abeloff MD; Jewell WR; Costanzi JJ; Farrar WB; Osborne CK
    J Clin Oncol; 1996 Jan; 14(1):46-51. PubMed ID: 8558219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes.
    Bearman SI; Overmoyer BA; Bolwell BJ; Taylor CW; Shpall EJ; Cagnoni PJ; Mechling BE; Ronk B; Barón AE; Purdy MH; Ross M; Jones RB
    Bone Marrow Transplant; 1997 Dec; 20(11):931-7. PubMed ID: 9422471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
    Vitolo U; Cortellazzo S; Liberati AM; Freilone R; Falda M; Bertini M; Botto B; Cinieri S; Levis A; Locatelli F; Lovisone E; Marmont F; Pizzuti M; Rossi A; Viero P; Barbui T; Grignani F; Resegotti L
    J Clin Oncol; 1997 Feb; 15(2):491-8. PubMed ID: 9053470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.
    Fumoleau P; Kerbrat P; Romestaing P; Fargeot P; Brémond A; Namer M; Schraub S; Goudier MJ; Mihura J; Monnier A; Clavère P; Serin D; Seffert P; Pourny C; Facchini T; Jacquin JP; Sztermer JF; Datchary J; Ramos R; Luporsi E
    J Clin Oncol; 2003 Jan; 21(2):298-305. PubMed ID: 12525522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
    Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
    J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of high-dose epirubicin (EPI) plus cyclophosphamide (CPA) with G-CSF for breast cancer patients with visceral metastases or hormone-independent tumors: a trial of the Japan Clinical Oncology Group.
    Takashima S; Saeki T; Adachi I; Watanabe T; Sasaki Y; Murai H; Tabei T; Ogita M; Sano M; Kanda K; Shimoyama M
    Jpn J Clin Oncol; 1997 Oct; 27(5):325-30. PubMed ID: 9390210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer.
    Honkoop AH; Luykx-de Bakker SA; Hoekman K; Meyer S; Meyer OW; van Groeningen CJ; van Diest PJ; Boven E; van der Wall E; Giaccone G; Wagstaff J; Pinedo HM
    Oncologist; 1999; 4(2):106-11. PubMed ID: 10337380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodes.
    Fumoleau P; Chauvin F; Namer M; Bugat R; Tubiana-Hulin M; Guastalla JP; Delozier T; Kerbrat P; Devaux Y; Bonneterre J; Filleul A; Clavel M
    J Clin Oncol; 2001 Feb; 19(3):612-20. PubMed ID: 11157010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects on blood coagulation of adjuvant CNF (cyclophosphamide, novantrone, 5-fluorouracil) chemotherapy in stage II breast cancer patients.
    Pectasides D; Tsavdaridis D; Aggouridaki C; Tsavdaridou V; Visvikis A; Tsatalas K; Fountzilas G
    Anticancer Res; 1999; 19(4C):3521-6. PubMed ID: 10629646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine factors in the outcome of systemic adjuvant therapy of early breast cancer.
    Bianco AR; De Placido S; Perrone F; Carlomagno C; De Laurentiis M; Del Mastro L; Lauria R; Marinelli A; Gallo C
    Ann N Y Acad Sci; 1993 Nov; 698():330-8. PubMed ID: 8279772
    [No Abstract]   [Full Text] [Related]  

  • 20. Multicycle high-dose chemotherapy and filgrastim-mobilized peripheral-blood progenitor cells in women with high-risk stage II or III breast cancer: five-year follow-up.
    Basser RL; To LB; Collins JP; Begley CG; Keefe D; Cebon J; Bashford J; Durrant S; Szer J; Kotasek D; Juttner CA; Russell I; Maher DW; Olver I; Sheridan WP; Fox RM; Green MD
    J Clin Oncol; 1999 Jan; 17(1):82-92. PubMed ID: 10458221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.